GENE ONLINE|News &
Opinion
Blog

JAK Inhibitor
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
GSK to Acquire Biopharmaceutical Company Sierra Oncology for $1.9B
2022-04-17
The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
2022-02-16
FDA Approves Incyte’s Jakafi for Chronic Graft-Versus-Host Disease
2021-09-23
Pfizer’s JAK1 Inhibitor Impresses in Phase 3 Atopic Dermatitis Trial
2020-11-12
Pfizer Announces Positive Top-Line Results for JAK Inhibitor in Ankylosing Spondylitis Trial
2020-11-08
Lilly, Incyte Gaining Ground in the Fight against Alopecia Areata
2020-11-01
Torii Pharma’s Corectim Ointment Features in Japan’s NHI Drug Price List
2020-04-26
Pfizer’s Dupixent Rival Meets Endpoints in Atopic Dermatitis Trial
2020-04-05
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top